Literature DB >> 29511992

Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.

M E M van der Noordaa1, F H van Duijnhoven1, M E Straver2, E J Groen3, M Stokkel4, C E Loo5, P H M Elkhuizen6, N S Russell6, M T F D Vrancken Peeters7.   

Abstract

BACKGROUND: Axillary lymph node dissection (ALND) is frequently performed for node-positive (cN+) breast cancer patients. Combining positron emission tomography/computed tomography (PET/CT) before-NST and the MARI (marking axillary lymph nodes with radioactive iodine seeds) procedure after neoadjuvant systemic therapy (NST) has the potential for avoiding unnecessary ALNDs. This report presents the results from implementation of this strategy.
METHODS: All breast cancer patients treated with NST at the Netherlands Cancer Institute who underwent a PET/CT and the MARI procedure from July 2014 to July 2017 were included in the study. All the patients underwent tailored axillary treatment according to a protocol based on the combined results of PET/CT before NST and the MARI procedure after NST. With this protocol, patients showing one to three FDG-avid axillary lymph nodes (ALNs) on PET/CT (cN<4) and a tumor-negative MARI node receive no further axillary treatment. All cN (<4) patients with a tumor-positive MARI node receive locoregional radiotherapy, as well as patients with four or more FDG-avid ALNs [cN(4+)] and a tumor-negative MARI node after NST. An ALND is performed only for cN(4+) patients with a tumor-positive MARI node.
RESULTS: The data of 159 patients who received a PET/CT before NST and a MARI procedure after NST were analyzed. Of these patients, 110 had one to three FDG-avid ALNs and 49 patients showed four or more FDG-avid ALNs on PET/CT before NST. For 130 patients (82%), ALND was omitted. Locoregional radiotherapy was administered to 91 patients (57%), and 39 patients (25%) received no further axillary treatment.
CONCLUSION: Combining pre-NST axillary staging with PET/CT and post-NST staging with the MARI procedure resulted in an 82% reduction of ALNDs for cN + breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29511992     DOI: 10.1245/s10434-018-6404-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.

Authors:  Marieke E M van der Noordaa; Ileana Ioan; Emiel J Rutgers; Erik van Werkhoven; Claudette E Loo; Rosie Voorthuis; Jelle Wesseling; Japke van Urk; Terry Wiersma; Vincent Dezentje; Marie-Jeanne T F D Vrancken Peeters; Frederieke H van Duijnhoven
Journal:  Ann Surg Oncol       Date:  2021-05-12       Impact factor: 5.344

Review 2.  De-Escalating Axillary Surgery in Node-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.

Authors:  Sabine R de Wild; Janine M Simons; Marie-Jeanne T F D Vrancken Peeters; Marjolein L Smidt; Linetta B Koppert
Journal:  Breast Care (Basel)       Date:  2021-08-17       Impact factor: 2.860

3.  Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.

Authors:  Ariane A van Loevezijn; Marieke E M van der Noordaa; Erik D van Werkhoven; Claudette E Loo; Gonneke A O Winter-Warnars; Terry Wiersma; Koen K van de Vijver; Emilie J Groen; Charlotte F J M Blanken-Peeters; Bas J G L Zonneveld; Gabe S Sonke; Frederieke H van Duijnhoven; Marie-Jeanne T F D Vrancken Peeters
Journal:  Ann Surg Oncol       Date:  2020-12-02       Impact factor: 5.344

4.  Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer.

Authors:  Giacomo Montagna; Yiwei Tong; Mathilde Ritter; Jeremy Levi; Walter P Weber; Xiaosong Chen; Kunwei Shen
Journal:  Oncology       Date:  2021-03-18       Impact factor: 3.734

Review 5.  Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Huan Wang; Xiaoyun Mao
Journal:  Drug Des Devel Ther       Date:  2020-06-18       Impact factor: 4.162

6.  Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.

Authors:  Janine M Simons; Thiemo J A van Nijnatten; Carmen C van der Pol; Ernest J T Luiten; Linetta B Koppert; Marjolein L Smidt
Journal:  Ann Surg       Date:  2019-03       Impact factor: 12.969

7.  Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.

Authors:  B Schermers; V Franke; E A Rozeman; B A van de Wiel; A Bruining; M W Wouters; W J van Houdt; B Ten Haken; S H Muller; C Bierman; T J M Ruers; C U Blank; A C J van Akkooi
Journal:  Br J Surg       Date:  2019-03-18       Impact factor: 6.939

8.  Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer.

Authors:  J M Simons; M L M A van Pelt; A W K S Marinelli; M E Straver; A M Zeillemaker; L M Pereira Arias-Bouda; T J A van Nijnatten; L B Koppert; K K Hunt; M L Smidt; E J T Luiten; C C van der Pol
Journal:  Br J Surg       Date:  2019-10-08       Impact factor: 6.939

9.  Novel Uses of Radioactive Seeds in Surgical Oncology: A Case Series.

Authors:  Michèle Beniey; Kerianne Boulva; Ahmad Kaviani; Erica Patocskai
Journal:  Cureus       Date:  2019-09-20

10.  Feasibility of radioguided occult lesion localization of clip-marked lymph nodes for tailored axillary treatment in breast cancer patients treated with neoadjuvant systemic therapy.

Authors:  Daan Hellingman; Maarten L Donswijk; Gonneke A O Winter-Warnars; Petra de Koekkoek-Doll; Marilyn Pinas; Yvonne Budde-van Namen; Johan Westerga; Marie-Jeanne T F D Vrancken Peeters; Nikola Kimmings; Marcel P M Stokkel
Journal:  EJNMMI Res       Date:  2019-10-24       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.